GSK Crumbles As Blood Cancer Comeback Falls Unexpectedly Short

GSK's stock declined 5.1% after the FDA granted a narrower-than-expected approval for its multiple myeloma treatment, Blenrep, limiting its use to patients who have undergone at least three prior lines of therapy. This restricted approval follows the drug's previous withdrawal from the market due to a failed confirmatory study and despite a recent trial showing efficacy against Johnson & Johnson's Darzalex, as the FDA advisory committee had raised concerns over significant ocular side effects. While GSK's Chief Scientific Officer highlighted the approval as a 'significant milestone' addressing unmet patient needs, the limited indication and safety profile impacted investor sentiment.

Analysis

GSK's stock declined 5.1% following the FDA's narrower-than-expected approval for its blood cancer treatment, Blenrep, on Friday. The agency approved Blenrep only for multiple myeloma patients who have undergone at least three prior lines of therapy, significantly restricting its market potential compared to GSK's target of second-line treatment. This limited indication reflects a cautious regulatory stance despite the drug's clinical efficacy.

The approval comes after Blenrep was previously pulled from the market in 2022 due to a failed confirmatory study. While the recent DREAMM-7 study demonstrated significant improvements in overall survival and progression-free survival against Johnson & Johnson's Darzalex, an FDA advisory panel raised substantial concerns regarding severe ocular side effects, including corneal ulcers and vision loss. The panel's vote that benefits did not outweigh risks heavily influenced the restricted label.

Despite GSK's Chief Scientific Officer, Tony Wood, calling the approval a "significant milestone" and emphasizing Blenrep's unique administration flexibility in community settings, the market reaction indicates investor disappointment. The narrow patient population and persistent safety concerns will likely constrain Blenrep's commercial uptake and revenue contribution, impacting GSK's pharmaceutical growth trajectory.

Key Decisions for Investors

• Investors should assess the revised commercial outlook for Blenrep, considering the significantly reduced addressable patient population and potential for slow uptake due to severe ocular side effects.
• Monitor GSK's future pipeline developments and regulatory interactions for other key assets, as Blenrep's limited approval highlights ongoing challenges in their oncology portfolio.
• Consider the broader implications for GSK's pharmaceutical division, as this outcome may temper growth expectations and increase scrutiny on their R&D productivity and risk management strategies.